NovaBay Pharmaceuticals, Inc. (NBY) P/E Ratio History
Historical price-to-earnings valuation from 2009 to 2025
Loading P/E history...
NBY Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, NovaBay Pharmaceuticals, Inc. (NBY) trades at a price-to-earnings ratio of -0.7x, with a stock price of $1.88 and trailing twelve-month earnings per share of $0.55.
The current P/E is 100% below its 5-year average of 5557.1x. Over the past five years, NBY's P/E has ranged from a low of 10.7x to a high of 18080.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, NBY trades at a 103% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, NBY trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NBY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NBY P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $281M | 21.6 | 1.54Best | +13% | |
| $2B | 36.3 | 4.85 | +1883%Best | |
| $11B | 14.1Lowest | - | +190% | |
| $341B | 22.4 | 4.01 | +8% | |
| $8B | 21.6 | 6.84 | +7% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
NBY Historical P/E Data (2009–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $6.40 | $0.60 | 10.7x | -100% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $2.90 | $0.22 | 13.2x | -100% |
| FY2010 Q2 | Wed Jun 30 2010 00:00:00 GM | $329066.25 | $18.20 | 18080.6x | +225% |
| FY2010 Q1 | Wed Mar 31 2010 00:00:00 GM | $336875.63 | $51.63 | 6524.8x | +17% |
| FY2009 Q4 | $315438.09 | $99.94 | 3156.3x | -43% |
Average P/E for displayed period: 5557.1x
See NBY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NBY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NBY vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNBY — Frequently Asked Questions
Quick answers to the most common questions about buying NBY stock.
Is NBY stock overvalued or undervalued?
NBY trades at -0.7x P/E, below its 5-year average of 5557.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does NBY's valuation compare to peers?
NovaBay Pharmaceuticals, Inc. P/E of -0.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is NBY's PEG ratio?
NBY PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2009-2025.